ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1971

Muscle Pathology in Patients with Primary Biliary Cholangitis
Abstract Number: 1453

Musculoskeletal Involvement in Systemic Lupus Erythematosus: Insights from a Survey of Lupus Experts
Abstract Number: 0352

Musculoskeletal Ultrasound Findings in Children with Psoriasis
Abstract Number: 0804

Mutated NOD2 Controls IL-2 Production in Blau Syndrome Patients and Mice
Abstract Number: L02

Mutational Analysis of UNC93B1 Identifies Regulatory Regions Mutated in Human SLE
Abstract Number: PP13

My Four Pillars of Wellness: How Sleep, Diet, Exercise and Stress Reduction Enable Me to Define My Life and not let Sjögren’s Define Me
Abstract Number: 1529

Mycophenolate Mofetil Use in Clinical Practice: Persistence on Therapy and Long-term Adverse Events in a Multicentric Cohort of Scleroderma Patients
Abstract Number: 0291

Myopathy Related to Small-to-medium-sized Vessel Vasculitis: Immunopathological Characteristics
Abstract Number: 2514

Myositis Triad Subset Is Associated with High Mortality in Immune Checkpoint Inhibitor- Induced Myositis
Abstract Number: 1622

Myositis-associated Autoantibodies in Juvenile Myositis Are Associated with Severe Disease Features and Mortality
Abstract Number: 0567

N-Terminal Pro-Brain Natriuretic Peptide Correlates Strongly with Cardiovascular Damage in Systemic Lupus Erythematous (SLE): A Cross-sectional Study
Abstract Number: 1602

NADPH Oxidase Exerts a B Cell-intrinsic Contribution to Lupus Risk by Modulating Endosomal Toll-like Receptor (TLR) Signals
Abstract Number: 1138

Nailfold Capillaroscopy Findings in Patients with Idiopathic Inflammatory Myopathies and Its Association to Autoantibodies
Abstract Number: 0610

Nailfold Capillaroscopy for Prediction of Novel Severe Organ Involvement in Systemic Sclerosis
Abstract Number: 0623

Nailfold Capillaroscopy in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) Treated with Nintedanib

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].